{"id":3712,"date":"2023-02-06T14:19:00","date_gmt":"2023-02-06T19:19:00","guid":{"rendered":"https:\/\/cpdc.ca\/psma-1007\/"},"modified":"2025-06-11T18:57:20","modified_gmt":"2025-06-11T22:57:20","slug":"psma-1007","status":"publish","type":"page","link":"https:\/\/cpdc.ca\/fr\/psma-1007\/","title":{"rendered":"PSMA-1007"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"3712\" class=\"elementor elementor-3712 elementor-311\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-80f81b8 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"80f81b8\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-04adb44\" data-id=\"04adb44\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2b49475 elementor-widget elementor-widget-heading\" data-id=\"2b49475\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">PSMA-1007<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b26ac29 elementor-widget elementor-widget-heading\" data-id=\"b26ac29\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">D\u00e9tecter. Diagnostiquer. D\u00e9cider.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fa4d86c elementor-widget elementor-widget-text-editor\" data-id=\"fa4d86c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLe cancer de la prostate est la troisi\u00e8me cause de d\u00e9c\u00e8s par cancer chez les hommes canadiens. Afin d&rsquo;augmenter le nombre d&rsquo;agents diagnostiques sp\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\u00e9 un <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04644822?term=NCT04644822&amp;rank=1\">essai clinique de phase III <\/a>sur le [<sup>(18)<\/sup> F]PSMA-1007. Cet agent cible la prot\u00e9ine de l&rsquo;antig\u00e8ne membranaire sp\u00e9cifique de la prostate (PSMA) qui est surexprim\u00e9e dans le cancer de la prostate. Le PSMA-1007 devrait \u00eatre disponible pour les patients canadiens en 2026.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-b88a1f2 elementor-section-content-middle animated-slow elementor-section-boxed elementor-section-height-default elementor-section-height-default elementor-invisible\" data-id=\"b88a1f2\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;animation&quot;:&quot;fadeIn&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-10ebc86\" data-id=\"10ebc86\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-aa31043 elementor-widget elementor-widget-image\" data-id=\"aa31043\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"624\" height=\"271\" src=\"https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/06\/psma3.png\" class=\"attachment-full size-full wp-image-4247\" alt=\"\" srcset=\"https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/06\/psma3.png 624w, https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/06\/psma3-300x130.png 300w\" sizes=\"(max-width: 624px) 100vw, 624px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0fc22f6 elementor-widget elementor-widget-text-editor\" data-id=\"0fc22f6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Image adapt\u00e9e de Giesel, F.L., Hadaschik, B., Cardinale, J. <em>et al.<\/em> PSMA-1007 marqu\u00e9 au F-18 : biodistribution, dosim\u00e9trie des rayonnements et validation histopathologique des l\u00e9sions tumorales chez des patients atteints d&rsquo;un cancer de la prostate. <em>Eur J Nucl Med Mol Imaging<\/em> <strong>44<\/strong>, 678\u2013688 (2017). https:\/\/doi.org\/10.1007\/s00259-016-3573-4. L&rsquo;image n&rsquo;a subi aucune modification. Cliquez <a href=\"https:\/\/s100.copyright.com\/AppDispatchServlet?title=The%20value%20of%2018F-PSMA-1007%20PET%2FCT%20in%20identifying%20non-metastatic%20high-risk%20prostate%20cancer&amp;author=Jun-jie%20Hong%20et%20al&amp;contentID=10.1186%2Fs13550-020-00730-1&amp;copyright=The%20Author%28s%29&amp;publication=2191-219X&amp;publicationDate=2020-11-10&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY\">ici<\/a> pour obtenir la licence Creative Commons permettant sa publication.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-7074dff\" data-id=\"7074dff\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-436e575 elementor-widget elementor-widget-text-editor\" data-id=\"436e575\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>CPDC d\u00e9tient les droits de licence exclusifs pour le PSMA-1007 d&rsquo;ABX GmbH (Radeberg, Allemagne) pour fabriquer, commercialiser et distribuer l&rsquo;agent d&rsquo;imagerie au Canada. CPDC s&rsquo;efforce de mettre sur le march\u00e9 canadien un outil de diagnostic du cancer de la prostate d&rsquo;une importance cruciale.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>PSMA-1007 D\u00e9tecter. Diagnostiquer. D\u00e9cider. Le cancer de la prostate est la troisi\u00e8me cause de d\u00e9c\u00e8s par cancer chez les hommes canadiens. Afin d&rsquo;augmenter le nombre d&rsquo;agents diagnostiques sp\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\u00e9 un essai clinique de phase III sur le [(18) F]PSMA-1007. Cet agent cible la prot\u00e9ine de &#8230; <a title=\"PSMA-1007\" class=\"read-more\" href=\"https:\/\/cpdc.ca\/fr\/psma-1007\/\" aria-label=\"Read more about PSMA-1007\">Read more<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-3712","page","type-page","status-publish"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.9 - aioseo.com -->\n\t<meta name=\"description\" content=\"PSMA-1007 D\u00e9tecter. Diagnostiquer. D\u00e9cider. Le cancer de la prostate est la troisi\u00e8me cause de d\u00e9c\u00e8s par cancer chez les hommes canadiens. Afin d\u2019augmenter le nombre d\u2019agents diagnostiques sp\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\u00e9 un essai clinique de phase III sur le [(18) F]PSMA-1007. Cet agent cible la prot\u00e9ine de\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/cpdc.ca\/fr\/psma-1007\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.9\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"CPDC - Centre for Probe Development and Commercialization\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"PSMA-1007 - CPDC\" \/>\n\t\t<meta property=\"og:description\" content=\"PSMA-1007 D\u00e9tecter. Diagnostiquer. D\u00e9cider. Le cancer de la prostate est la troisi\u00e8me cause de d\u00e9c\u00e8s par cancer chez les hommes canadiens. Afin d\u2019augmenter le nombre d\u2019agents diagnostiques sp\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\u00e9 un essai clinique de phase III sur le [(18) F]PSMA-1007. Cet agent cible la prot\u00e9ine de\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/cpdc.ca\/fr\/psma-1007\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/05\/CPDC-Icon-White-no-bg.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/05\/CPDC-Icon-White-no-bg.png\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2023-02-06T19:19:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-06-11T22:57:20+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"PSMA-1007 - CPDC\" \/>\n\t\t<meta name=\"twitter:description\" content=\"PSMA-1007 D\u00e9tecter. Diagnostiquer. D\u00e9cider. Le cancer de la prostate est la troisi\u00e8me cause de d\u00e9c\u00e8s par cancer chez les hommes canadiens. Afin d\u2019augmenter le nombre d\u2019agents diagnostiques sp\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\u00e9 un essai clinique de phase III sur le [(18) F]PSMA-1007. Cet agent cible la prot\u00e9ine de\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/05\/CPDC-Icon-White-no-bg.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/psma-1007\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/psma-1007\\\/#listItem\",\"name\":\"PSMA-1007\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/psma-1007\\\/#listItem\",\"position\":2,\"name\":\"PSMA-1007\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/#listItem\",\"name\":\"Home\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/#organization\",\"name\":\"Just another WordPress site\",\"description\":\"Centre for Probe Development and Commercialization\",\"url\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/cpdc.ca\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/CPDC-Icon-White-no-bg.png\",\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/psma-1007\\\/#organizationLogo\",\"width\":668,\"height\":528},\"image\":{\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/psma-1007\\\/#organizationLogo\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/psma-1007\\\/#webpage\",\"url\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/psma-1007\\\/\",\"name\":\"PSMA-1007 - CPDC\",\"description\":\"PSMA-1007 D\\u00e9tecter. Diagnostiquer. D\\u00e9cider. Le cancer de la prostate est la troisi\\u00e8me cause de d\\u00e9c\\u00e8s par cancer chez les hommes canadiens. Afin d\\u2019augmenter le nombre d\\u2019agents diagnostiques sp\\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\\u00e9 un essai clinique de phase III sur le [(18) F]PSMA-1007. Cet agent cible la prot\\u00e9ine de\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/psma-1007\\\/#breadcrumblist\"},\"datePublished\":\"2023-02-06T14:19:00-05:00\",\"dateModified\":\"2025-06-11T18:57:20-04:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/\",\"name\":\"Just another WordPress site\",\"description\":\"Centre for Probe Development and Commercialization\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/cpdc.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"PSMA-1007 - CPDC","description":"PSMA-1007 D\u00e9tecter. Diagnostiquer. D\u00e9cider. Le cancer de la prostate est la troisi\u00e8me cause de d\u00e9c\u00e8s par cancer chez les hommes canadiens. Afin d\u2019augmenter le nombre d\u2019agents diagnostiques sp\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\u00e9 un essai clinique de phase III sur le [(18) F]PSMA-1007. Cet agent cible la prot\u00e9ine de","canonical_url":"https:\/\/cpdc.ca\/fr\/psma-1007\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/cpdc.ca\/fr\/psma-1007\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/cpdc.ca\/fr\/#listItem","position":1,"name":"Home","item":"https:\/\/cpdc.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/cpdc.ca\/fr\/psma-1007\/#listItem","name":"PSMA-1007"}},{"@type":"ListItem","@id":"https:\/\/cpdc.ca\/fr\/psma-1007\/#listItem","position":2,"name":"PSMA-1007","previousItem":{"@type":"ListItem","@id":"https:\/\/cpdc.ca\/fr\/#listItem","name":"Home"}}]},{"@type":"Organization","@id":"https:\/\/cpdc.ca\/fr\/#organization","name":"Just another WordPress site","description":"Centre for Probe Development and Commercialization","url":"https:\/\/cpdc.ca\/fr\/","logo":{"@type":"ImageObject","url":"https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/05\/CPDC-Icon-White-no-bg.png","@id":"https:\/\/cpdc.ca\/fr\/psma-1007\/#organizationLogo","width":668,"height":528},"image":{"@id":"https:\/\/cpdc.ca\/fr\/psma-1007\/#organizationLogo"}},{"@type":"WebPage","@id":"https:\/\/cpdc.ca\/fr\/psma-1007\/#webpage","url":"https:\/\/cpdc.ca\/fr\/psma-1007\/","name":"PSMA-1007 - CPDC","description":"PSMA-1007 D\u00e9tecter. Diagnostiquer. D\u00e9cider. Le cancer de la prostate est la troisi\u00e8me cause de d\u00e9c\u00e8s par cancer chez les hommes canadiens. Afin d\u2019augmenter le nombre d\u2019agents diagnostiques sp\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\u00e9 un essai clinique de phase III sur le [(18) F]PSMA-1007. Cet agent cible la prot\u00e9ine de","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/cpdc.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/cpdc.ca\/fr\/psma-1007\/#breadcrumblist"},"datePublished":"2023-02-06T14:19:00-05:00","dateModified":"2025-06-11T18:57:20-04:00"},{"@type":"WebSite","@id":"https:\/\/cpdc.ca\/fr\/#website","url":"https:\/\/cpdc.ca\/fr\/","name":"Just another WordPress site","description":"Centre for Probe Development and Commercialization","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/cpdc.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"CPDC - Centre for Probe Development and Commercialization","og:type":"article","og:title":"PSMA-1007 - CPDC","og:description":"PSMA-1007 D\u00e9tecter. Diagnostiquer. D\u00e9cider. Le cancer de la prostate est la troisi\u00e8me cause de d\u00e9c\u00e8s par cancer chez les hommes canadiens. Afin d\u2019augmenter le nombre d\u2019agents diagnostiques sp\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\u00e9 un essai clinique de phase III sur le [(18) F]PSMA-1007. Cet agent cible la prot\u00e9ine de","og:url":"https:\/\/cpdc.ca\/fr\/psma-1007\/","og:image":"https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/05\/CPDC-Icon-White-no-bg.png","og:image:secure_url":"https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/05\/CPDC-Icon-White-no-bg.png","article:published_time":"2023-02-06T19:19:00+00:00","article:modified_time":"2025-06-11T22:57:20+00:00","twitter:card":"summary_large_image","twitter:title":"PSMA-1007 - CPDC","twitter:description":"PSMA-1007 D\u00e9tecter. Diagnostiquer. D\u00e9cider. Le cancer de la prostate est la troisi\u00e8me cause de d\u00e9c\u00e8s par cancer chez les hommes canadiens. Afin d\u2019augmenter le nombre d\u2019agents diagnostiques sp\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\u00e9 un essai clinique de phase III sur le [(18) F]PSMA-1007. Cet agent cible la prot\u00e9ine de","twitter:image":"https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/05\/CPDC-Icon-White-no-bg.png"},"aioseo_meta_data":{"post_id":"3712","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2025-06-18 21:32:32","updated":"2025-06-18 21:32:32","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/cpdc.ca\/fr\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tPSMA-1007\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/cpdc.ca\/fr\/"},{"label":"PSMA-1007","link":"https:\/\/cpdc.ca\/fr\/psma-1007\/"}],"_links":{"self":[{"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/pages\/3712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/comments?post=3712"}],"version-history":[{"count":33,"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/pages\/3712\/revisions"}],"predecessor-version":[{"id":4264,"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/pages\/3712\/revisions\/4264"}],"wp:attachment":[{"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/media?parent=3712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}